

1 Analysis of the *in vitro* transcriptional response of human pharyngeal epithelial cells to  
2 adherent *Streptococcus pneumoniae*: evidence for a distinct response to encapsulated strains

3

4

5

6

7

8 Running title: Transcriptional response to pneumococcal adherence

9

10

11 Hester J. Bootsma<sup>1</sup>, Michael Egmont-Petersen<sup>2</sup>, Peter W M. Hermans<sup>1,\*</sup>

12

13

14 <sup>1</sup> Laboratory of Pediatric Infectious Diseases, Radboud University Nijmegen Medical Centre,  
15 Nijmegen, The Netherlands.

16

17 <sup>2</sup> Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen,  
18 The Netherlands

19

20 \* Corresponding author. Mailing address: Laboratory of Pediatric Infectious Diseases,  
21 Radboud University Nijmegen Medical Centre, PO Box 9101 (Route 224), 6500 HB  
22 Nijmegen, The Netherlands. Phone: (31)-24-3666406. Fax: (31)-24-3666352. E-mail:  
23 P.Hermans@cukz.umcn.nl.

24

24 **ABSTRACT NB: 250 words or fewer!!**

25

26 Infection of the human host by *Streptococcus pneumoniae* begins with colonization of the  
27 nasopharynx, which is mediated by adherence of bacteria to respiratory epithelium. Several  
28 studies have indicated an important role for the pneumococcal capsule in this process. Here,  
29 we used microarrays to characterize the *in vitro* transcriptional response of human  
30 nasopharyngeal epithelial Detroit 562 cells to adherence of serotype 2-encapsulated strain  
31 D39, serotype 19F-encapsulated strain G54, serotype 4-encapsulated strain TIGR4, and their  
32 nonencapsulated derivatives ( $\Delta cps$ ). In total, 322 genes were found to be upregulated in  
33 response to adherent pneumococci. Twenty-two genes were commonly induced, including  
34 those encoding several cytokines (e.g., IL-1 $\beta$ , IL-6), chemokines (e.g., IL-8, CXCL1/2), and  
35 transcriptional regulators (e.g., FOS), consistent with an innate immune response mediated by  
36 Toll-like receptor signaling. Interestingly, 85% of genes were induced specifically by one or  
37 more encapsulated strains, suggestive of a capsule-dependent response, although purified  
38 type 2 polysaccharides alone had no effect. Over a third of these loci encoded products  
39 predicted to be involved in transcriptional regulation and signal transduction, in particular the  
40 MAPK signaling pathways. Real-time PCR of a subset of ten genes confirmed microarray  
41 data and showed a time-dependent upregulation of especially innate immunity genes.  
42 Downregulation of epithelial genes was most pronounced upon adherent D39 $\Delta cps$ , as 68% of  
43 the 161 genes identified was only repressed using this nonencapsulated strain. In conclusion,  
44 we identified a subset of host genes specifically induced by encapsulated strains during *in*  
45 *vitro* adherence, underlining the complexity of interactions occurring during the initial stages  
46 of pneumococcal infection.

47

47 **INTRODUCTION**

48

49 The gram-positive bacterium *Streptococcus pneumoniae* is a major cause of mucosal  
50 infections such as otitis media, and of more severe invasive diseases like pneumonia and  
51 septicemia. Particularly children, elderly people, and immunocompromized patients are  
52 affected by this pathogen. Colonization of the nasopharynx, mediated by adherence of the  
53 bacterium to epithelial cells of the upper respiratory tract, is common and usually  
54 asymptomatic. It is, however, also the critical first step for infection of the host by *S.*  
55 *pneumoniae* (7). In addition, nasopharyngeal carriage of *S. pneumoniae* has been proposed to  
56 serve as a main source for transmission of this pathogen within the community (16). Neither  
57 host nor bacterial factors required for adherence and colonization have been completely  
58 characterized yet.

59 *S. pneumoniae* expresses several proteins described to be important for its virulence, such  
60 as pneumolysin and choline-binding proteins (CBPs) (reviewed in (35)). Of these, CbpA  
61 (also known as PspC) and CbpG have been shown to function as an adhesin for eukaryotic  
62 cells (34,45). Another major virulence factor is the polysaccharide capsule, of which at least  
63 90 different serotypes are known (19). Pneumococci can occur in different colony variants  
64 known as opaque and transparent phase variants, characterized by high and low levels of  
65 capsule production, respectively. Generally, transparent phase variants display enhanced  
66 adherence and colonization ability compared to opaque variants (24,53). Apparently, reduced  
67 capsule expression (down to 20% of wild-type levels) benefits the initial adherence and  
68 colonization of pneumococci, possibly by allowing better exposure of surface proteins  
69 important for adherence (32). In line with this, pneumococci in close contact with murine or  
70 cultured epithelial cells appeared to contain substantially lower levels of capsule compared to  
71 bacteria more distant from cells (17). Interestingly, a recent study showed that, despite its

72 inhibitory effect on adherence, the presence of capsule does confer an advantage during  
73 colonization: only encapsulated strains are able to transit efficiently from the luminal mucus  
74 to the epithelial surface (40). Finally, there is an absolute requirement for capsule in systemic  
75 infections, with varying degrees of severity depending on capsular serotype (9,49). Once  
76 inside the host, the capsule is considered to protect *S. pneumoniae* against host immunity,  
77 preventing, for instance, complement-mediated opsonophagocytosis (1).

78 The innate immune system provides a critical non-specific first line of defense against  
79 microorganisms, and is essential for proper development of subsequent adaptive immune  
80 responses. Key elements of innate immunity are the so-called pattern recognition receptors  
81 (PRRs), of which the membrane-bound Toll-like receptors (TLRs) play a central role in the  
82 response to microbes (22). TLRs recognize conserved microbial structures referred to as  
83 pathogen-associated molecular patterns, such as those occurring in bacterial lipoteichoic acid  
84 (LTA), lipopolysaccharide (LPS), and DNA (unmethylated CpG motifs). Involvement of  
85 both TLR2 and TLR4 in the host response to pneumococci has been demonstrated using  
86 various *in vitro* and *in vivo* infection models, mediated by recognition of pneumococcal LTA  
87 (TLR2) and pneumolysin (TLR4) (18,33,48,50,52). Recent studies also indicated a role for  
88 TLR9 in host defense against pneumococcal infection, particularly at the early stages (2,36).  
89 The central signaling adaptor myeloid differentiation factor-88 (MyD88) mediates signal  
90 transduction from most of the TLRs upon ligand binding (22), and has been shown to be  
91 crucial for the host response to pneumococcal infection (3,9,23,26). Subsequent activation of  
92 the nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathway leads to production of proinflammatory cytokines  
93 such as TNF $\alpha$ , IL-1, and IL-6.

94 DNA microarray technology is particularly suitable to examine the host response on a  
95 global scale, as several thousand genes can be surveyed at once. Thus far, only a few studies  
96 have taken this approach to identify host factors involved in pneumococcal colonization and

97 subsequent disease. Rogers *et al.* have analyzed the transcriptional response of a human  
98 monocytic cell line to pneumococci, focusing on pneumolysin-dependent and -independent  
99 gene expression (44). They identified 40 genes responsive independent of pneumolysin, and  
100 142 pneumolysin-responsive genes, including those encoding IL-8, MIP-1 $\beta$ , lysozyme, and  
101 caspases 4 and 6 (44). Examination of gene expression profiles in middle ears of rats during  
102 early and late stages of *S. pneumoniae*-induced otitis media identified transient expression of  
103 cytokines and persistent upregulation of several transcription factors including c-jun and c-  
104 myc (11,30). Similarly, transcriptional profiling of cortex and hippocampus of rats during  
105 acute pneumococcal meningitis identified 598 differentially regulated genes, associated  
106 mainly with growth control, signal transduction, cell death/survival, cytoskeleton, and innate  
107 and adaptive immunity (12). Finally, a microarray-based screen for host genes with increased  
108 expression during colonization of the murine nasal mucosa identified siderocalin, a  
109 component of innate immunity involved in iron-sequestering (39).

110 As mentioned, the first interaction between the pneumococcus and the host in colonization  
111 and subsequent infection occurs during adherence of the bacterium to the respiratory  
112 epithelial cell surface. To gain molecular insight into the response of the epithelium during  
113 this interaction, we used microarrays to characterize the transcriptional profile of the human  
114 nasopharyngeal epithelial cell line Detroit 562 after 2 hours adherence of *S. pneumoniae*  
115 wild-type strains D39 (serotype 2), G54 (serotype 19F), and TIGR4 (serotype 4). Considering  
116 the crucial role of pneumococcal capsule in this process, we simultaneously analyzed the  
117 response to the three corresponding isogenic capsule-locus deletion mutants (D39 $\Delta cps$ ,  
118 G54 $\Delta cps$ , and TIGR4 $\Delta cps$ ), as well as to purified type 2 capsular polysaccharides. This  
119 approach allowed us to identify epithelial genes responsive in a capsule-dependent and -  
120 independent fashion. Finally, we used real-time PCR to follow expression of a small selection  
121 of genes over time.

122

## 122 MATERIALS AND METHODS

123

124 **Cell culture.** The human pharyngeal epithelial cell line Detroit 562 (ATCC CCL-138) was  
125 grown and maintained at 37°C in a 5% CO<sub>2</sub> atmosphere in RPMI 1640 without phenol red  
126 (Invitrogen, The Netherlands) supplemented with 1 mM sodium pyruvate and 10% (vol/vol)  
127 fetal calf serum (FCS).

128

129 **Pneumococcal strains, growth conditions, and pneumococcal polysaccharides.** *S.*  
130 *pneumoniae* strains used in this study were the wild-type isolates D39 (D39WT; serotype 2;  
131 NCTC 7466), G54 (G54WT; serotype 19F; (13)), TIGR4 (51) and their isogenic capsule-  
132 locus (*cps*) deletion mutants D39 $\Delta$ *cps*, G54 $\Delta$ *cps*, and TIGR4 $\Delta$ *cps* constructed as follows. A  
133  $\Delta$ *cps* PCR fragment, consisting of a kanamycin-resistance cassette flanked by *dexA* and *aliA*  
134 sequences, was amplified from *S. pneumoniae* strain D39(FP22) with primer pair FI4 and  
135 PE21 as described (41). This PCR product was introduced into *S. pneumoniae* by  
136 transformation, and kanamycin-resistant colonies, in which the entire capsule gene cluster  
137 was replaced with the kanamycin-resistance gene, were verified by PCR. For adherence  
138 assays, bacteria were grown to mid-exponential phase in Todd Hewitt broth supplemented  
139 with 5 g/L yeast extract (THY) and stored in 1-ml aliquots in THY containing 15% glycerol  
140 at -80°C. The number of colony forming units per milliliter (CFU/ml) was determined by  
141 plating serial 10-fold dilutions of test aliquots on Colombia blood agar plates. Before each  
142 assay, bacteria were thawed rapidly, washed once with RPMI 1640 medium without phenol  
143 red containing 1% FCS, and resuspended to the required CFU/ml in the same medium.

144 Purified pneumococcal polysaccharide type 2 powder was purchased from the American  
145 Type Culture Collection (ATCC, Manassas, VA), suspended in distilled water and used at a  
146 final concentration of 20  $\mu$ g/ml.

147

148       **Exposure of cells to *S. pneumoniae*.** Adherence of pneumococci to epithelial cells was  
149 assayed essentially as described with a few modifications (25). Briefly, monolayers of Detroit  
150 562 cells in tissue culture dishes (60 mm; samples for microarray analysis) or 6-well plates  
151 (35 mm; samples for time-curve) were washed twice with PBS, after which bacteria were  
152 added at a multiplicity of infection of 20:1 (bacteria:cells). Uninfected control cells were  
153 incubated with RPMI 1640 medium with 1% FCS only (mock-infected). After a  
154 predetermined incubation period (2h for microarray; 30 min, 2h, and 4 h for time-curve),  
155 nonadherent bacteria were removed by three washes with PBS. For quantification of  
156 adherence, epithelial cells were subsequently detached by treatment with 25% Trypsin, 1 mM  
157 EDTA in PBS and lysed by the addition of ice-cold 0.025% Triton X-100 in PBS. Serial 10-  
158 fold dilutions were plated on blood agar plates to count the number of adherent bacteria, and  
159 corrected mathematically to account for small differences in count in the initial inoculum.

160

161       **RNA isolation.** After washing, Detroit 562 cells were lysed directly in the tissue culture  
162 dish by addition of RLT buffer (Qiagen Benelux B.V.), collected with a rubber policeman,  
163 and transferred to a microcentrifuge tube. Subsequently, total RNA was isolated using the  
164 RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Total RNA was  
165 isolated from independent triplicate experiments. Quality and integrity of the purified RNA  
166 was verified by running all samples on an Agilent 2100 Bioanalyzer (Agilent Technologies,  
167 Waldbronn, Germany).

168

169       **Microarray hybridization.** RNA was labeled using recommended protocols supplied by  
170 the manufacturer (Affymetrix, Santa Clara, CA). Briefly, double-stranded cDNA was  
171 synthesized from 6 µg of total RNA using a T7-oligo(dT) primer. The cDNA was purified

172 and converted to cRNA in an *in vitro* transcription reaction in the presence of biotinylated  
173 nucleotides. Subsequently, the biotinylated cRNA was purified and quantified by  
174 spectrophotometric methods. cRNA yield was adjusted for carryover of unlabeled total RNA.  
175 Twenty micrograms of cRNA was fragmented for 35 min at 94°C, and hybridized to  
176 Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays for 16 hours. After  
177 hybridization, the GeneChips were washed and stained using a GeneChip Fluidics Station  
178 450 (Affymetrix), and scanned with an Affymetrix GeneChip Scanner.

179

180 **Microarray data analysis.** The Affymetrix expression data were analyzed using the  
181 software package Gene Spring, version 7.3 (Agilent). All experiments (infected and mock-  
182 infected cells) were performed in triplicate to allow assessment of in-group variation. First,  
183 expression data obtained from infected cells was normalized to the median of the uninfected  
184 control samples. An initial selection of genes was made based on a 1.5-fold change in  
185 expression relative to that of uninfected control cells. Subsequently, an error model based on  
186 replicate measurements was defined in Gene Spring, and significance of differential  
187 expression was established using ANOVA and the false-discovery rate method (FDR) by  
188 Benjamini and Hochberg (5) to correct for multiple testing.

189 Transcriptional profiling of Detroit cells in response to adherence of *S. pneumoniae* strains  
190 was performed in three separate experiments. First, the response to adherent D39, D39Δ*cps*,  
191 and G54Δ*cps* was analyzed. Gene expression data of epithelial cells after adherence of wild-  
192 type *S. pneumoniae* strain G54 was collected second, and normalized to a separate set of  
193 uninfected control cells (obtained at the same time). The last experiment consisted of cells  
194 exposed to TIGR4, TIGR4Δ*cps*, low-dose D39Δ*cps*, purified type 2 capsular  
195 polysaccharides, and uninfected control cells used for normalization. In all cases, genes were



196 considered significantly up- or down regulated when  $p < 0.05$ , and the average fold-change  $\geq$   
197 2.0 or  $\leq 0.5$ , respectively.

198 Gene annotation and functional classification was based on information from the Gene  
199 Ontology (4) or KEGG (20) databases. Significant overlap of specific sets of upregulated or  
200 downregulated genes with KEGG pathways was assessed using GeneSpring.

201

202 **Real-time PCR.** Real-time quantitative PCR was used to validate selected data from  
203 microarray experiments and to follow expression of a subset of genes over time. Total RNA  
204 (2  $\mu\text{g}$ ) was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit  
205 according to the instructions provided by the manufacturer (Applied Biosystems, Foster City,  
206 CA). Duplicate quantitative PCR assays were performed on 1  $\mu\text{l}$  of 10x diluted cDNA using  
207 TaqMan Gene Expression Assays (Applied Biosystems) of several target genes: ADRB2  
208 (Hs00240532\_s1), CXCL2 (Hs00601975\_m1), DUSP5 (Hs00244839\_m1), GAPDH  
209 (Hs99999905\_m1), IL6 (Hs00174131\_m1), IL8 (Hs00174103\_m1), MAP3K8  
210 (Hs00178297\_m1), MOAP1 (Hs00377893\_g1), NFKBIA (Hs00153283\_m1), TNFAIP3  
211 (Hs00234712\_m1), TRIB1 (Hs00179769\_m1), and 18S (Hs99999901\_s1). All assay were  
212 done in 10- $\mu\text{l}$  reactions containing TaqMan<sup>®</sup> Universal PCR Master Mix, 20X TaqMan<sup>®</sup>  
213 Gene Expression Assay Mix, and cDNA on a Applied Biosystems 7500 FAST real-time PCR  
214 system according to the manufacturer's instructions. The relative quantitation method ( $\Delta\Delta C_T$ )  
215 (31) was used to evaluate quantitative variation in gene expression between a particular  
216 experimental condition and control (uninfected) cells relative to each gene examined. The  
217 GAPDH amplicon was used as the endogenous control for normalization of data.

218

219 **IL-6 ELISA.** Concentrations of IL-6 in Detroit 562 culture supernatants were measured  
220 by a commercial ELISA kit (PeliKine Compact, Sanquin, Amsterdam, The Netherlands)

221 according to the instructions of the manufacturer. Levels of IL-6 were calculated based on  
222 standards provided with the kit, and expressed as fold-increase relative to levels measured in  
223 culture supernatants from uninfected control cells.

224

225 **Cytotoxicity assay.** As an indicator of cell viability during pneumococcal exposure,  
226 released cytosolic lactate dehydrogenase (LDH) was quantified in cell culture supernatants  
227 using the CytoTox96 Non-radioactive Cytotoxicity Assay kit (Promega, Madison, WI) as  
228 recommended by the manufacturer.

229

229 **RESULTS**

230

231 **Transcriptional response of epithelial cells exposed to *S. pneumoniae*.** To be able to  
232 distinguish between a capsule-dependent and capsule-independent host response to  
233 pneumococcal adherence, we constructed an isogenic capsule-locus deletion mutant of wild-  
234 type, serotype 2-encapsulated *S. pneumoniae* strain D39. Consistent with earlier studies  
235 showing a negative influence of capsule expression on adherence and colonization ability of  
236 *S. pneumoniae* (17,24,53), the nonencapsulated derivative D39 $\Delta$ *cps* displayed significantly  
237 higher *in vitro* adherence to epithelial cells compared to the D39 wild-type strain (Fig. 1).  
238 Further, pneumococcal adherence was found to increase in both a dose- and time-dependent  
239 manner (not shown).

240 Next, we used microarray analysis to characterize the transcriptional response of the  
241 human pharyngeal epithelial cells after 2 hours adherence of D39 and D39 $\Delta$ *cps*. During this  
242 time frame, no adverse effect of pneumococcal exposure on cell viability was evident since  
243 no substantial LDH release was detected, while the level of adherence was at or near  
244 maximum (not shown). By selecting gene probes that showed at least a two-fold increase in  
245 expression compared to uninfected cells, a total of 136 probes representing 100 genes were  
246 found to be upregulated in Detroit cells in response to the two adherent *S. pneumoniae* strains  
247 (Fig. 2A, Supplementary Table S1). Of these, 19 were found to be induced in response both  
248 wild-type and  $\Delta$ *cps* D39, whereas expression of the vast majority (72) appeared to be  
249 upregulated upon adherence of the wild-type strain only (Fig. 2A), indicative of a capsule-  
250 dependent set of host response genes. To determine whether this gene set is truly induced by  
251 the presence of encapsulated strains, or merely the result of suppression of expression of  
252 those particular genes by the higher number of adherent nonencapsulated bacteria, we used an  
253 additional, lower dose of D39 $\Delta$ *cps* giving adherence levels equivalent to its encapsulated

254 wild-type (Fig. 1). Subsequent microarray analysis of the transcriptional response of the  
255 Detroit cells to low-dose D39 $\Delta cps$  identified only four upregulated genes, none of which  
256 were identified with the previous two conditions (Supplementary Table S1). This clearly  
257 shows that the observed difference in response is not due to downregulation of gene  
258 expression by higher numbers of adherent nonencapsulated bacteria.

259 To examine if this particular expression profile was unique for the serotype 2 strain, or a  
260 more general capsule-dependent response, we included two additional, clinical isolates and  
261 their isogenic capsule mutants ( $\Delta cps$ ) in our analyses: serotype 19F-encapsulated G54, and  
262 TIGR4 of serotype 4. Again, the nonencapsulated derivatives showed greater levels of  
263 adherence compared to their wild-types in our *in vitro* assay (Fig. 1). Similar to our  
264 observations with D39, microarray analysis showed that the majority of the genes  
265 upregulated by adherent wild-type and  $\Delta cps$  strains were induced only in response to the  
266 encapsulated strains (Figs. 2B and 2C, Supplementary Table S1). Strikingly, the presence of  
267 the serotype 4 strain triggered a much stronger response than the other two strains: almost  
268 three times as many genes were found to be upregulated. Even so, a considerable overlap was  
269 observed between the three sets of capsule-dependent response genes (Fig. 2D).

270 Evidently, the transcriptional response of pharyngeal epithelial cells to adherent  
271 pneumococci is greatly affected by capsule expression of the bacteria. To find out if this  
272 response requires the context of bacterial cells, we analyzed the expression pattern of Detroit  
273 cells after a 2-hour incubation with purified type 2 capsular polysaccharides. Only four genes  
274 showed an increase in expression of 2-fold or more: *IGFBP5*, encoding insulin-like growth  
275 factor binding protein 5; *CRISP3*, coding for cysteine-rich secretory protein 3; and two  
276 hypothetical ORFs (Supplementary Table S1). Although none of these loci were induced by  
277 the serotype 2-encapsulated D39, one of the hypotheticals was upregulated in response to

278 TIGR4 and TIGR4 $\Delta$ *cps*, and the other three genes were also identified using the low-dose  
279 D39 $\Delta$ *cps*.

280

281 **Capsule-independent and capsule-dependent transcriptional responses.** Twenty-two  
282 genes were identified that can be considered part of the common host response to  
283 pneumococcal infection, as they were induced by all genetic strain backgrounds, in most  
284 cases regardless of capsule (Table 1). The majority of these commonly induced genes encode  
285 proteins known to play a role in the immune response, such as those encoding several  
286 cytokines (IL-1 $\beta$ , IL-6), chemokines (IL-8, CCL20, CXCL1-3), and transcriptional regulators  
287 (NF $\kappa$ BIA, FOS). Other commonly induced genes included *EGR1*, involved in transcriptional  
288 regulation of cell growth and differentiation, and *BIRC3* and *IER3*, whose products are  
289 proposed to be involved in inhibition of apoptosis.

290 Over 300 genes were found to be induced specifically upon adherence of one or more of  
291 the wild-type strains D39, G54, and TIGR4. These genes can be considered part of either a  
292 capsule-dependent (i.e., induced by multiple encapsulated strains tested) or capsular serotype-  
293 dependent (i.e., upregulated specifically by exposure to one) host response. Genes  
294 upregulated in response to adherent encapsulated pneumococci were distributed among a  
295 variety of functional categories, but were clearly enriched for genes predicted to encode  
296 proteins involved in signal transduction and regulation of transcription (Table 2,  
297 Supplementary Table S1). No function could be assigned to approximately 25% of the  
298 transcripts (Table 2).

299 Notably, a significant number of genes were upregulated in response to all encapsulated  
300 strains that are part of the so-called mitogen-activated protein kinase (MAPK) signaling  
301 pathways (Table 3), which influence a variety of cellular processes such as cell growth,  
302 differentiation, and apoptosis in response to a wide range of stimuli (42). For example,

303 *ADRB2* and *EGFR* encode receptors that can trigger the MAPK cascade upon binding of  
304 appropriate ligands, and several kinases and phosphates were identified that are involved in  
305 subsequent transduction of signals from the cell membrane to the nucleus (Table 3). Several  
306 of the other signal transduction molecules identified have been described to play a role in the  
307 immune response. For example, the gene encoding the IL-1 receptor-associated kinase 2  
308 (IRAK2) was induced specifically by D39; genes encoding two cytokines belonging to the  
309 TNF ligand family (TNFSF18 and TNFSF9), and annexin 1 (ANXA1) by TIGR4; the  
310 cytokine gene *LIF* and a suppressor of cytokine signaling (*SOCS1*) by both D39 and TIGR4;  
311 and the gene coding for GTP-binding protein GEM was upregulated in response to all three  
312 wild-type strains.

313 Close to 60 of the genes induced specifically in response to the encapsulated strains could  
314 be classified as transcription factors. These are predicted to be involved in various biological  
315 processes, such as immunoregulatory genes (*JUN*, Fos gene family members *FOSL1* and  
316 *FOSB*, *PRDMI*, and *CEBPB*), and regulation of cell growth and differentiation (7 members  
317 of the Krüppel-like factor (KLF) family). Several transcription factors were particularly  
318 strongly induced by the presence of TIGR4 and/or D39: *ATF3*, identified as negative  
319 regulator of TLR4 (14), and two other members of the early growth response family (*EGR2*  
320 and *EGR3*). Other genes of interest included several apoptosis-related genes, and several  
321 genes encoding extracellular matrix receptors (*ITGAV*, *ITGB2*, *SDFR1*) and a receptor-  
322 ligand (*PLAU*, urokinase plasminogen activator), which was also found to be upregulated at  
323 48 hr in a rat otitis media model (11).

324 Remarkably, more than half of the upregulated genes appeared to be capsular serotype-  
325 specific, i.e., specifically induced by TIGR4 (Fig. 2D). In addition to the transcription factors  
326 and signal transduction proteins mentioned above, predominant functional classes represented

327 in this gene set were transporters (e.g., 4 solute carrier family proteins), and cell proliferation  
328 (e.g., epithelial membrane protein EMP1) (Table 2).

329 To validate our microarray data, relative transcript levels were determined by quantitative  
330 real-time PCR on a selection of common and capsule-dependent host response genes, namely  
331 the innate immune genes *IL6*, *IL8*, *CXCL2*, *NFκBIA*, and *TNFAIP3*; the MAPK pathways  
332 genes *MAP3K8*, *DUSP5*, *ADRB2*, and *TRIB*; and apoptosis-related gene *MOAPI*. Overall,  
333 expression ratios obtained by microarray and real-time PCR analysis were concordant for all  
334 six conditions examined ( $R^2 = 0.84$ ; Fig. 3).

335 To examine if changes observed in gene expression corresponded with changes in protein  
336 expression, we measured IL-6 in supernatants of Detroit cells after pneumococcal adherence.  
337 In correlation with the gene expression data, protein levels of IL-6 started to increase after 2  
338 hr exposure of epithelial cells to all *S. pneumoniae* strains (not shown).

339

340 **Expression of selected genes over time.** The global transcriptional profiling described  
341 above focused on a two-hour time period of adherence. Based on the lists generated by these  
342 analyses, we selected a subset of five common innate immunity genes (see above) and  
343 followed their expression over time (30 min, 2h, and 4h) by real-time PCR upon adherence of  
344 the D39 and TIGR4 wild-type strains and their nonencapsulated derivatives (Fig. 4A). In  
345 addition, we examined expression of five capsule-dependent genes at the different time points  
346 (Fig. 4B). No difference in expression between uninfected control cells and infected cells was  
347 observed for the control 18S rRNA gene under any condition (data not shown). Expression of  
348 the common response genes was upregulated upon adherence in a time-dependent manner: no  
349 significant increase in expression compared to uninfected control cells at the earliest time  
350 point (30 min), while highest expression levels were achieved after 4h adherence (Fig. 4A).  
351 As expected, the response of these innate immunity genes to adherent encapsulated and

352 nonencapsulated strains was comparable. The same was true for one of the genes of the  
353 MAPK signaling pathway, *MAP3K8* (Fig. 4B), in agreement with the microarray results  
354 (Table 1). The other three MAPK genes showed a capsule-dependent expression pattern,  
355 particularly at the 2-hour time point and in response to the TIGR4 strain (Fig. 4B). However,  
356 both the difference in induction between encapsulated and nonencapsulated strains and the  
357 overall fold-change of genes was less pronounced than originally determined by the  
358 microarray analysis. Furthermore, no upregulation of the apoptosis modulating gene *MOAPI*  
359 could be demonstrated by real-time PCR under any condition (Fig. 4B), while it appeared to  
360 be induced 2-fold by TIGR4WT in our microarray analysis (Supplementary Table S1). For all  
361 genes examined, the presence of TIGR4 and TIGR4 $\Delta$ *cps* resulted in the highest levels of  
362 expression changes, particularly at the latest time point. Interestingly, measurement of LDH  
363 release indicated that cell viability was also affected by the TIGR4 strains after 4h, while  
364 LDH release by cells infected with the D39 strains showed levels similar to the uninfected  
365 control cells (Fig. 5). Finally, we investigated the influence of low-dose D39 $\Delta$ *cps* and  
366 purified type 2 capsular polysaccharides (20 and 50  $\mu$ g/ml) on epithelial gene expression, but  
367 no upregulation was observed for any of the ten genes examined (data not shown).

368

369 **Genes downregulated in response to *S. pneumoniae*.** Expression of 142 genes  
370 (represented by 150 gene probes) was found to be decreased at least two-fold upon adherence  
371 of wild-type and  $\Delta$ *cps* D39 (Fig. 6, Supplementary Table S2). These repressed genes mainly  
372 belonged to metabolism, regulation of transcription, cell cycle, and, most predominantly,  
373 unknown functional categories (Table 4). Contrary to our observations made with  
374 upregulated genes, the vast majority (111) of repressed genes were downregulated only in  
375 response to the nonencapsulated D39 $\Delta$ *cps*. In most cases, these genes showed a similar trend  
376 in response to strain D39WT, albeit to a lesser extent (e.g., 1.6-1.9 fold downregulation,



377 Supplementary Table S2). Interestingly, this response appeared to be specific for the D39  
378 genetic background: only eight genes were found to be repressed by adherent G54 wild-type  
379 or its nonencapsulated derivative G54 $\Delta$ *cps*, no genes were downregulated in response to  
380 TIGR4 $\Delta$ *cps*, and twenty-one genes to TIGR4 wild-type (Fig. 4, Table 4). Eight genes were  
381 downregulated in response to different strain backgrounds, among which *KRT4*, encoding  
382 cytoskeletal protein keratin 4; *CLDN8*, encoding membrane protein claudin 8 involved in  
383 cell-cell adhesion, and the anti-apoptotic gene *API5*.  
384

384 **DISCUSSION**

385

386 The interplay between host and pathogen during the infectious process is complex and  
387 dynamic, requiring multiple factors from either side during different stages of infection. For  
388 the pneumococcus, colonization of the human nasopharynx is a prerequisite for infection (7).  
389 Colonization is initiated by adherence of *S. pneumoniae* to the host surface, influenced by  
390 several outer surface components, one of which is the pneumococcal capsule. For the host,  
391 the response tends to be focused on clearing the pathogen, mediated by activation of innate  
392 and adaptive defense mechanisms. A few studies have attempted to characterize the host  
393 response to pneumococci, both by using *in vitro* and *in vivo* models of infection  
394 (11,12,30,39,44). In this study, we examined the global transcriptional response of human  
395 epithelial cells to pneumococcal adherence *in vitro*, in particular in relation to the  
396 pneumococcal capsule.

397 A total of 322 genes were found to be upregulated in the human pharyngeal epithelial  
398 Detroit 562 cell line in response to adherent wild-type and nonencapsulated *S. pneumoniae*  
399 strains. In all cases, adherence of the encapsulated strains triggered a much greater  
400 transcriptional response than adherence of their isogenic nonencapsulated derivatives. This  
401 difference in gene induction does not appear to be associated with the number of adherent  
402 bacteria, as all wild-type strains adhered approximately one to two orders of magnitude less  
403 than their nonencapsulated mutants. Moreover, the results obtained with the lower dose  
404 D39 $\Delta$ *cps* showed that this differential gene expression is indeed the consequence of  
405 upregulation of the genes in question in response to the encapsulated strain, not  
406 downregulation by the greater number of nonencapsulated bacteria attached to the cell  
407 surface. Detroit 562 genes induced by all pneumococcal strains tested included those  
408 encoding several cytokines, chemokines, and transcriptional regulators. Such transcriptional

409 profiles are consistent with a general innate immune response to bacteria mediated by Toll-  
410 like receptor signaling, i.e., a stereotyped gene expression program (8). For *S. pneumoniae*,  
411 activation of TLR2, TLR4, and TLR9 has been reported, by respectively pneumococcal cell  
412 wall components, pneumolysin, and, most likely, CpG DNA (2,18,33,36,48,50). Since both  
413 wild-type strains and their  $\Delta cps$  derivatives contain these TLR ligands, stimulation of the  
414 TLRs is likely to occur by all strains used in our experimental setup, resulting in the common  
415 induction of, for instance, IL-6 gene expression and protein levels. Similar expression  
416 profiles have been reported in other studies using various cell types and *in vivo* models,  
417 underscoring the generality of this response. In respiratory epithelial cells, expression of IL-8  
418 and CXCL2/3 (MIP-2ab) was shown to be increased in response to D39 (15,43). In a human  
419 monocytic cell line, expression of IL-8, but not IL-1 $\beta$ , was found to be induced after 3 hours  
420 exposure to pneumococci (44), while IL-1 $\beta$  and IL-6 production was observed in monocytes  
421 after 24 hrs exposure (10). *In vivo*, levels of IL-1 $\beta$  and MIP-2ab were induced during early  
422 pneumococcal otitis media in rats (11), while AP-1 family transcription factors were induced  
423 both early and late during otitis media (11,30).

424 A large set of genes was found to be upregulated specifically upon adherence of the wild-  
425 type strains, suggestive of a capsule-dependent host response. For the most part, distinct  
426 genes sets were induced by serotype 2-encapsulated strain D39, serotype 19F-encapsulated  
427 strain G54, and serotype 4-encapsulated strain TIGR4, indicating that the observed response  
428 is largely capsular serotype-specific. The polysaccharide structures of capsular serotypes 2, 4  
429 and 19F are very diverse (6), potentially explaining the limited overlap in the induced genes  
430 sets. Incubation of Detroit cells with purified type 2 polysaccharides did not trigger the same  
431 transcriptional response as seen with the encapsulated strains, indicating that the capsule is  
432 best recognized in the context of (live) bacterial cells. Interestingly, adherence of the TIGR4  
433 strain had the most pronounced effect on epithelial gene expression, suggesting that strain

434 genetic background is also of importance during this interaction. Recognition of  
435 pneumococcal capsule by the host is not mediated by TLRs. In mice, it has been described to  
436 depend on another PRR, namely the C-type lectin receptor (CLR) SIGN-R1 (homologue of  
437 DC-SIGN), expressed by mouse splenic and peritoneal macrophages (21). For immune  
438 activation to occur upon antigen binding by CLRs, simultaneous signalling through TLRs by  
439 appropriate ligands is believed to be required (27). SIGN-R1 has been shown to be essential  
440 for host resistance to both systemic and pulmonary infections with *S. pneumoniae* strains of  
441 different serotypes (21,28,29). However, expression of a homologue of this receptor on  
442 human epithelial cells has not been reported yet, and the exact role for this or other lectin-  
443 type receptors in mediating the capsule-dependent response observed in our experimental  
444 setup remains to be determined.

445 The encapsulated strains appeared to particularly induce several components of MAPK  
446 signaling pathways. The MAP kinases play pivotal roles in various cellular processes,  
447 including cell growth, inflammation, and apoptosis (42). Three major subfamilies of MAP  
448 kinases have been identified: extracellular signal-regulated kinases (ERK1/2), p38 MAP  
449 kinases, and c-Jun kinases (JNK). Several studies have demonstrated activation of both the  
450 JNK and p38 MAPK pathways in response to pneumococci, in bronchial and lung epithelial  
451 cells as well as endothelial cells (37,38,47). Our results are consistent with preferential  
452 activation of the JNK and p38 MAPK pathways. In human endothelial cells, activation of  
453 MAPK pathways by nonencapsulated pneumococci was shown to induce programmed cell  
454 death or apoptosis, executed by caspases 6 and 9 (38). Similarly, nonencapsulated *S.*  
455 *pneumoniae* induced caspase-6 dependent apoptosis of lung epithelial cells (46). In both  
456 cases, encapsulated strains mainly induced cell death in absence of DNA fragmentation,  
457 indicative of necrosis rather than apoptosis. When examining the transcriptional response of  
458 monocytes to pneumococci, Rogers *et al.* observed no significant effect on cell viability, but

459 did report upregulation of caspases 4 and 6 (44). Here, we found induction of expression of  
460 several putative apoptosis-related genes, some of which have been described to induce  
461 apoptosis in a caspase-dependent manner (e.g., *MOAPI*, *EGLN3*), caspases themselves were  
462 not identified. Furthermore, no loss of cell viability was apparent during the 2-hour time  
463 period of adherence used for microarray analysis, although extended (4h) adherence of the  
464 TIGR4 strain did result in increased LDH release. For both endothelial and lung epithelial  
465 cells, caspase-dependent apoptosis was only observed after 16 hours of pneumococcal  
466 infection. It can, therefore, not be excluded that prolonged adherence will lead to apoptotic or  
467 necrotic cell death of the pharyngeal epithelial cells in our setup as well. Apoptosis can  
468 benefit both the pathogen, contributing to its virulence by inducing tissue injury, and the host,  
469 enhancing bacterial killing and controlling the inflammatory response (as opposed to  
470 necrosis). The induction of necrotic rather than apoptotic cell death by encapsulated strains  
471 could potentially be mediated by expression of some of the genes identified as capsule- (or  
472 serotype-) dependent in this study, but further experiments are needed to verify this  
473 hypothesis.

474 A total of 161 genes were found to be downregulated in the epithelial cells. This response  
475 appeared to be specific for the D39 genetic background, as very few genes were found to be  
476 repressed by wild-type or nonencapsulated G54. Moreover, this did not appear to be mediated  
477 by the capsule, as expression of the majority of genes was decreased upon adherence of the  
478 nonencapsulated D39 derivative only. Possibly, the absence of capsule allows greater access  
479 to other D39 surface components involved in eliciting this particular host response, an effect  
480 likely to be enhanced by the greater number of adherent D39 $\Delta$ *cps* compared to D39WT.

481 Adherence to and subsequent colonization of the nasopharyngeal epithelium is  
482 indispensable for pneumococcal infection. By analyzing the *in vitro* transcriptional response  
483 of human pharyngeal epithelial cells to pneumococcal adherence, we obtained evidence for a

484 subset of host genes specifically induced by encapsulated *S. pneumoniae* strains. *In vivo*, the  
485 situation is likely to be complicated by the presence of multiple bacterial species at the  
486 epithelial surface. For example, a synergistic increase in production of proinflammatory  
487 cytokines was observed in response to costimulation with *S. pneumoniae* and of *Haemophilus*  
488 *influenzae*, but *in vitro* by pharyngeal and lung epithelial cells (IL-8) and *in vivo* in the  
489 murine nasopharynx (MIP-2) (43). Future studies, for instance using more extended periods  
490 of adherence or exposure to mixed bacterial infections, will be required to exactly determine  
491 the role of the pneumococcal capsule in triggering the host response. Furthermore, our data  
492 suggest a central role for the TLR, lectin-type receptor, and MAP kinase pathways in defining  
493 the host response to pneumococci, emphasizing the complexity of the host-pathogen  
494 interaction, even at the earliest stages of the infectious cycle.  
495

495 **ACKNOWLEDGEMENTS**

496

497 We thank Tom Schonewille (Department of Immunology, Erasmus MC Rotterdam, The  
498 Netherlands) for technical assistance, and Mihai Netea for his critical reading of the  
499 manuscript. HJB is supported by IOP genomic grant IGE3002 of the Dutch Ministry of  
500 Economic Affairs.

501

501 **REFERENCES**

502

503 1. **Abeyta, M., G. G. Hardy, and J. Yother.** 2003. Genetic alteration of capsule type but  
504 not PspA type affects accessibility of surface-bound complement and surface antigens of  
505 *Streptococcus pneumoniae*. *Infect. Immun.* **71**:218-225.

506 2. **Albiger, B., S. Dahlberg, A. Sandgren, F. Wartha, K. Beiter, H. Katsuragi, S. Akira,**  
507 **S. Normark, and B. Henriques-Normark.** 2006. Toll-like receptor 9 acts at an early  
508 stage in host defence against pneumococcal infection. *Cell Microbiol.* **Epub ahead of**  
509 **print.**

510 3. **Albiger, B., A. Sandgren, H. Katsuragi, U. Meyer-Hoffert, K. Beiter, F. Wartha, M.**  
511 **Hornef, S. Normark, and B. H. Normark.** 2005. Myeloid differentiation factor 88-  
512 dependent signalling controls bacterial growth during colonization and systemic  
513 pneumococcal disease in mice. *Cell Microbiol.* **7**:1603-1615.

514 4. **Ashburner, M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P.**  
515 **Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-**  
516 **Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M.**  
517 **Rubin, and G. Sherlock.** 2000. Gene ontology: tool for the unification of biology. The  
518 Gene Ontology Consortium. *Nat. Genet.* **25**:25-29.

519 5. **Benjamini, Y. and Y. Hochberg.** 1995. Controlling the False Discovery Rate: a  
520 practical and powerful approach to multiple testing. *J. Royal Statistical Society B*  
521 **57**:289-300.

522 6. **Bentley, S. D., D. M. Aanensen, A. Mavroidi, D. Saunders, E. Rabinowitsch, M.**  
523 **Collins, K. Donohoe, D. Harris, L. Murphy, M. A. Quail, G. Samuel, I. C. Skovsted,**



- 524 **M. S. Kaltoft, B. Barrell, P. R. Reeves, J. Parkhill, and B. G. Spratt.** 2006. Genetic  
525 analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. *PLoS.*  
526 *Genet.* **2**:e31.
- 527 7. **Bogaert, D., R. de Groot, and P. W. Hermans.** 2004. *Streptococcus pneumoniae*  
528 colonisation: the key to pneumococcal disease. *Lancet Infect. Dis.* **4**:144-154.
- 529 8. **Boldrick, J. C., A. A. Alizadeh, M. Diehn, S. Dudoit, C. L. Liu, C. E. Belcher, D.**  
530 **Botstein, L. M. Staudt, P. O. Brown, and D. A. Relman.** 2002. Stereotyped and  
531 specific gene expression programs in human innate immune responses to bacteria. *Proc.*  
532 *Natl. Acad. Sci. U. S. A* **99**:972-977.
- 533 9. **Brueggemann, A. B., T. E. Peto, D. W. Crook, J. C. Butler, K. G. Kristinsson, and**  
534 **B. G. Spratt.** 2004. Temporal and geographic stability of the serogroup-specific invasive  
535 disease potential of *Streptococcus pneumoniae* in children. *J. Infect. Dis.* **190**:1203-1211.
- 536 10. **Cauwels, A., E. Wan, M. Leismann, and E. Tuomanen.** 1997. Coexistence of CD14-  
537 dependent and independent pathways for stimulation of human monocytes by gram-  
538 positive bacteria. *Infect. Immun.* **65**:3255-3260.
- 539 11. **Chen, A., H. S. Li, P. A. Hebda, A. Zeevi, and J. D. Swarts.** 2005. Gene expression  
540 profiles of early pneumococcal otitis media in the rat. *Int. J. Pediatr. Otorhinolaryngol.*  
541 **69**:1383-1393.
- 542 12. **Coimbra, R. S., V. Voisin, A. B. de Saizieu, R. L. Lindberg, D. Leppert, M. Wittwer,**  
543 **and S. L. Leib.** 2006. Gene expression in cortex and hippocampus during acute  
544 pneumococcal meningitis. *BMC. Biol.* **4**:15.

- 545 13. **Dopazo, J., A. Mendoza, J. Herrero, F. Caldara, Y. Humbert, L. Friedli, M.**  
546 **Guerrier, E. Grand-Schenk, C. Gandin, F. M. de, A. Polissi, G. Buell, G. Feger, E.**  
547 **Garcia, M. Peitsch, and J. F. Garcia-Bustos.** 2001. Annotated draft genomic sequence  
548 from a *Streptococcus pneumoniae* type 19F clinical isolate. *Microb. Drug Resist.* **7**:99-  
549 125.
- 550 14. **Gilchrist, M., V. Thorsson, B. Li, A. G. Rust, M. Korb, K. Kennedy, T. Hai, H.**  
551 **Bolouri, and A. Aderem.** 2006. Systems biology approaches identify ATF3 as a  
552 negative regulator of Toll-like receptor 4. *Nature* **441**:173-178.
- 553 15. **Graham, R. M. and J. C. Paton.** 2006. Differential role of CbpA and PspA in  
554 modulation of in vitro CXC chemokine responses of respiratory epithelial cells to  
555 infection with *Streptococcus pneumoniae*. *Infect. Immun.* **Epub ahead of print.**
- 556 16. **Gray, B. M. and H. C. Dillon, Jr.** 1988. Epidemiological studies of *Streptococcus*  
557 *pneumoniae* in infants: antibody to types 3, 6, 14, and 23 in the first two years of life. *J.*  
558 *Infect. Dis.* **158**:948-955.
- 559 17. **Hammerschmidt, S., S. Wolff, A. Hocke, S. Rosseau, E. Muller, and M. Rohde.**  
560 2005. Illustration of pneumococcal polysaccharide capsule during adherence and  
561 invasion of epithelial cells. *Infect. Immun.* **73**:4653-4667.
- 562 18. **Han, S. H., J. H. Kim, M. Martin, S. M. Michalek, and M. H. Nahm.** 2003.  
563 Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in  
564 stimulating Toll-like receptor 2. *Infect. Immun.* **71**:5541-5548.
- 565 19. **Henrichsen, J.** 1995. Six newly recognized types of *Streptococcus pneumoniae*. *J. Clin.*  
566 *Microbiol.* **33**:2759-2762.

- 567 20. **Kanehisa, M., S. Goto, S. Kawashima, Y. Okuno, and M. Hattori.** 2004. The KEGG  
568 resource for deciphering the genome. *Nucleic Acids Res.* **32**:D277-D280.
- 569 21. **Kang, Y. S., J. Y. Kim, S. A. Bruening, M. Pack, A. Charalambous, A. Pritsker, T.**  
570 **M. Moran, J. M. Loeffler, R. M. Steinman, and C. G. Park.** 2004. The C-type lectin  
571 SIGN-R1 mediates uptake of the capsular polysaccharide of *Streptococcus pneumoniae*  
572 in the marginal zone of mouse spleen. *Proc. Natl. Acad. Sci. U. S. A* **101**:215-220.
- 573 22. **Kawai, T. and S. Akira.** 2006. TLR signaling. *Cell Death. Differ.* **13**:816-825.
- 574 23. **Khan, A. Q., Q. Chen, Z. Q. Wu, J. C. Paton, and C. M. Snapper.** 2005. Both innate  
575 immunity and type 1 humoral immunity to *Streptococcus pneumoniae* are mediated by  
576 MyD88 but differ in their relative levels of dependence on toll-like receptor 2. *Infect.*  
577 *Immun.* **73**:298-307.
- 578 24. **Kim, J. O. and J. N. Weiser.** 1998. Association of intrastrain phase variation in quantity  
579 of capsular polysaccharide and teichoic acid with the virulence of *Streptococcus*  
580 *pneumoniae*. *J. Infect. Dis.* **177**:368-377.
- 581 25. **Kloosterman, T. G., W. T. Hendriksen, J. J. Bijlsma, H. J. Bootsma, S. A. van**  
582 **Hijum, J. Kok, P. W. Hermans, and O. P. Kuipers.** 2006. Regulation of glutamine and  
583 glutamate metabolism by GlnR and GlnA in *Streptococcus pneumoniae*. *J. Biol. Chem.*  
584 **281**:25097-25109.
- 585 26. **Koedel, U., T. Rupprecht, B. Angele, J. Heesemann, H. Wagner, H. W. Pfister, and**  
586 **C. J. Kirschning.** 2004. MyD88 is required for mounting a robust host immune response  
587 to *Streptococcus pneumoniae* in the CNS. *Brain* **127**:1437-1445.

- 588 27. **Koppel, E. A., K. P. van Gisbergen, T. B. Geijtenbeek, and K. Y. van.** 2005. Distinct  
589 functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in  
590 pathogen recognition and immune regulation. *Cell Microbiol.* **7**:157-165.
- 591 28. **Koppel, E. A., C. W. Wieland, V. van den Berg, M. Litjens, S. Florquin, van Kooyk**  
592 **Y., van der Poll T., and T. B. Geijtenbeek.** 2005. Specific ICAM-3 grabbing  
593 nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for  
594 defense against pulmonary *Streptococcus pneumoniae* infection. *Eur. J. Immunol.*  
595 **35**:2962-2969.
- 596 29. **Lanoue, A., M. R. Clatworthy, P. Smith, S. Green, M. J. Townsend, H. E. Jolin, K.**  
597 **G. Smith, P. G. Fallon, and A. N. McKenzie.** 2004. SIGN-R1 contributes to protection  
598 against lethal pneumococcal infection in mice. *J. Exp. Med.* **200**:1383-1393.
- 599 30. **Lin, J., Y. Tsuboi, W. Pan, G. S. Giebink, G. L. Adams, and Y. Kim.** 2002. Analysis  
600 by cDNA microarrays of altered gene expression in middle ears of rats following  
601 pneumococcal infection. *Int. J. Pediatr. Otorhinolaryngol.* **65**:203-211.
- 602 31. **Livak, K. J. and T. D. Schmittgen.** 2001. Analysis of relative gene expression data  
603 using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**:402-  
604 408.
- 605 32. **Magee, A. D. and J. Yother.** 2001. Requirement for capsule in colonization by  
606 *Streptococcus pneumoniae*. *Infect. Immun.* **69**:3755-3761.
- 607 33. **Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M.**  
608 **Thompson, E. Kurt-Jones, J. C. Paton, M. R. Wessels, and D. T. Golenbock.** 2003.  
609 Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal  
610 infection. *Proc. Natl. Acad. Sci. USA* **100**:1966-1971.

- 611 34. **Mann, B., C. Orihuela, J. Antikainen, G. Gao, J. Sublett, T. K. Korhonen, and E.**  
612 **Tuomanen.** 2006. Multifunctional role of choline binding protein G in pneumococcal  
613 pathogenesis. *Infect. Immun.* **74**:821-829.
- 614 35. **Mitchell, T. J.** 2000. Virulence factors and the pathogenesis of disease caused by  
615 *Streptococcus pneumoniae*. *Res. Microbiol.* **151**:413-419.
- 616 36. **Mogensen, T. H., S. R. Paludan, M. Kilian, and L. Ostergaard.** 2006. Live  
617 *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* activate  
618 the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific  
619 patterns. *J. Leukoc. Biol.* **80**:267-277.
- 620 37. **N'Guessan, P. D., S. Hippenstiel, M. O. Etouem, J. Zahlten, W. Beermann, D.**  
621 **Lindner, B. Opitz, M. Witzernath, S. Rosseau, N. Suttorp, and B. Schmeck.** 2006.  
622 *Streptococcus pneumoniae* induced p38 MAPK- and NF-kappaB-dependent COX-2  
623 expression in human lung epithelium. *Am. J. Physiol Lung Cell Mol. Physiol*  
624 **290**:L1131-L1138.
- 625 38. **N'Guessan, P. D., B. Schmeck, A. Ayim, A. C. Hocke, B. Brell, S. Hammerschmidt,**  
626 **S. Rosseau, N. Suttorp, and S. Hippenstiel.** 2005. *Streptococcus pneumoniae* R6x  
627 induced p38 MAPK and JNK-mediated caspase-dependent apoptosis in human  
628 endothelial cells. *Thromb. Haemost.* **94**:295-303.
- 629 39. **Nelson, A. L., J. M. Barasch, R. M. Bunte, and J. N. Weiser.** 2005. Bacterial  
630 colonization of nasal mucosa induces expression of siderocalin, an iron-sequestering  
631 component of innate immunity. *Cell Microbiol.* **7**:1404-1417.

- 632 40. **Nelson, A. L., A. M. Roche, J. M. Gould, K. Chim, A. J. Ratner, and J. N. Weiser.**  
633 2006. Capsule enhances pneumococcal colonization by limiting mucus-mediated  
634 clearance. *Infect. Immun.* **Epub ahead of print.**
- 635 41. **Pearce, B. J., F. Iannelli, and G. Pozzi.** 2002. Construction of new unencapsulated  
636 (rough) strains of *Streptococcus pneumoniae*. *Res. Microbiol.* **153**:243-247.
- 637 42. **Pearson, G., F. Robinson, G. T. Beers, B. E. Xu, M. Karandikar, K. Berman, and**  
638 **M. H. Cobb.** 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and  
639 physiological functions. *Endocr. Rev.* **22**:153-183.
- 640 43. **Ratner, A. J., E. S. Lysenko, M. N. Paul, and J. N. Weiser.** 2005. Synergistic  
641 proinflammatory responses induced by polymicrobial colonization of epithelial surfaces.  
642 *Proc. Natl. Acad. Sci. U. S. A* **102**:3429-3434.
- 643 44. **Rogers, P. D., J. Thornton, K. S. Barker, D. O. McDaniel, G. S. Sacks, E. Swiatlo,**  
644 **and L. S. McDaniel.** 2003. Pneumolysin-dependent and -independent gene expression  
645 identified by cDNA microarray analysis of THP-1 human mononuclear cells stimulated  
646 by *Streptococcus pneumoniae*. *Infect. Immun.* **71**:2087-2094.
- 647 45. **Rosenow, C., P. Ryan, J. N. Weiser, S. Johnson, P. Fontan, A. Ortqvist, and H. R.**  
648 **Masure.** 1997. Contribution of novel choline-binding proteins to adherence, colonization  
649 and immunogenicity of *Streptococcus pneumoniae*. *Mol. Microbiol.* **25**:819-829.
- 650 46. **Schmeck, B., R. Gross, P. D. N'Guessan, A. C. Hocke, S. Hammerschmidt, T. J.**  
651 **Mitchell, S. Rosseau, N. Suttorp, and S. Hippenstiel.** 2004. *Streptococcus*  
652 *pneumoniae*-induced caspase 6-dependent apoptosis in lung epithelium. *Infect. Immun.*  
653 **72**:4940-4947.

- 654 47. **Schmeck, B., K. Moog, J. Zahlten, L. van, V, P. D. N'Guessan, B. Opitz, S. Rosseau,**  
655 **N. Suttorp, and S. Hippenstiel.** 2006. *Streptococcus pneumoniae* induced c-Jun-N-  
656 terminal kinase- and AP-1-dependent IL-8 release by lung epithelial BEAS-2B cells.  
657 *Respir. Res.* 7:98.
- 658 48. **Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer,**  
659 **U. B. Gobel, J. R. Weber, and R. R. Schumann.** 2003. Lipoteichoic acid (LTA) of  
660 *Streptococcus pneumoniae* and *Staphylococcus aureus* activates immune cells via Toll-  
661 like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas  
662 TLR-4 and MD-2 are not involved. *J. Biol. Chem.* 278:15587-15594.
- 663 49. **Sjostrom, K., C. Spindler, A. Ortqvist, M. Kalin, A. Sandgren, S. Kuhlmann-**  
664 **Berenzon, and B. Henriques-Normark.** 2006. Clonal and capsular types decide  
665 whether pneumococci will act as a primary or opportunistic pathogen. *Clin. Infect. Dis.*  
666 42:451-459.
- 667 50. **Srivastava, A., P. Henneke, A. Visintin, S. C. Morse, V. Martin, C. Watkins, J. C.**  
668 **Paton, M. R. Wessels, D. T. Golenbock, and R. Malley.** 2005. The apoptotic response  
669 to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal  
670 disease. *Infect. Immun.* 73:6479-6487.
- 671 51. **Tettelin, H., K. E. Nelson, I. T. Paulsen, J. A. Eisen, T. D. Read, S. Peterson, J.**  
672 **Heidelberg, R. T. DeBoy, D. H. Haft, R. J. Dodson, A. S. Durkin, M. Gwinn, J. F.**  
673 **Kolonay, W. C. Nelson, J. D. Peterson, L. A. Umayam, O. White, S. L. Salzberg, M.**  
674 **R. Lewis, D. Radune, E. Holtzapple, H. Khouri, A. M. Wolf, T. R. Utterback, C. L.**  
675 **Hansen, L. A. McDonald, T. V. Feldblyum, S. Angiuoli, T. Dickinson, E. K. Hickey,**  
676 **I. E. Holt, B. J. Loftus, F. Yang, H. O. Smith, J. C. Venter, B. A. Dougherty, D. A.**

- 677 **Morrison, S. K. Hollingshead, and C. M. Fraser.** 2001. Complete genome sequence of  
678 a virulent isolate of *Streptococcus pneumoniae*. *Science* **293**:498-506.
- 679 52. **van Rossum, A. M., E. S. Lysenko, and J. N. Weiser.** 2005. Host and bacterial factors  
680 contributing to the clearance of colonization by *Streptococcus pneumoniae* in a murine  
681 model. *Infect. Immun.* **73**:7718-7726.
- 682 53. **Weiser, J. N., R. Austrian, P. K. Sreenivasan, and H. R. Masure.** 1994. Phase  
683 variation in pneumococcal opacity: relationship between colonial morphology and  
684 nasopharyngeal colonization. *Infect. Immun.* **62**:2582-2589.
- 685



685 **LEGENDS TO FIGURES**

686

687 **Figure 1. *In vitro* adherence of *S. pneumoniae*.** Adherence of wild-type *S. pneumoniae*  
688 strains D39, G54, and TIGR4 and their isogenic nonencapsulated derivatives ( $\Delta cps$ ) to  
689 Detroit 562 human pharyngeal epithelial cells. Data were obtained from three independent  
690 experiments and presented as means  $\pm$  standard errors of the mean.

691

692 **Figure 2. Distribution of genes upregulated in epithelial cells in response to adherent**  
693 **pneumococci.** A. Distribution of epithelial genes induced by adherent serotype 2-  
694 encapsulated D39WT and its nonencapsulated derivative D39 $\Delta cps$ . B. Distribution of  
695 epithelial genes induced by adherent serotype 19F-encapsulated G54WT and its  
696 nonencapsulated derivative G54 $\Delta cps$ . C. Distribution of epithelial genes induced by adherent  
697 serotype 4-encapsulated TIGR4WT and its nonencapsulated derivative TIGR4 $\Delta cps$ . D.  
698 Distribution of epithelial genes induced by the three wild-type *S. pneumonia* strains. The  
699 number of genes in each area within the Venn diagrams is indicated.

700

701 **Figure 3. Validation of microarray data by real-time PCR.** Ratios of transcript abundance  
702 in infected versus uninfected cells obtained by microarray analysis ( $x$  axis) or real-time PCR  
703 ( $y$  axis).

704

705 **Figure 4. Real-time PCR analysis of gene expression over time.**

706 Expression of specific genes (indicated at the top of each graph) was measured by real-time  
707 PCR after predetermined time point of adherence ( $x$  axis). Log<sub>2</sub> ratios of infected cells/control  
708 cells are the averages of two separate experiments. The dashed line indicates a two-fold  
709 change in expression relative to uninfected control cells.

710

711 **Figure 5. Cytotoxicity of epithelial cells upon adherence of pneumococci.** Pneumococcal  
712 strains were allowed to adhere to Detroit 562 cells for time periods indicated on x axis after  
713 which cytotoxicity was assessed by LDH release.

714

715 **Figure 6. Distribution of genes downregulated in pharyngeal epithelial Detroit 562 cells.**  
716 Distribution of epithelial genes repressed by adherent wild-type strains D39WT, G54WT and  
717 TIGR4WT and the isogenic nonencapsulated derivatives D39 $\Delta$ *cps* and G54 $\Delta$ *cps*. The  
718 number of genes in each area within the Venn diagrams is indicated. The hatched ellipse  
719 represents genes repressed in response to G54 $\Delta$ *cps*. No genes were found to be repressed in  
720 response to TIGR4 $\Delta$ *cps*.

721 **Table 1. Common response genes in pharyngeal epithelial Detroit 562 cells during pneumococcal adherence<sup>1</sup>.**

Locus	Description / Molecular Function	Fold-change <sup>2</sup> in response to:					
		D39WT	D39Δcps	G54WT	G54Δcps	TIGR4WT	TIGR4Δcps
<b>Immune Response</b>							
IL-1β	Interleukin 1β	3.5	2.4	- <sup>3</sup>	2.2	2.3	1.5
IL-6	Interleukin 6	4.7	2.7	1.5	2.5	10.5	2.8
IL-8	Interleukin 8	9.6	5.8	3.1	5.8	8.4	3.8
CCL20	Chemokine (C-C motif) ligand 20	-	5.7	-	4.8	5.0	2.6
CXCL1	Chemokine (C-X-C motif) ligand 1	3.9	3.3	1.7	3.5	2.8	2.0
CXCL2	Chemokine (C-X-C motif) ligand 2	6.4	4.6	3.6	5.6	9.1	4.6
CXCL3	Chemokine (C-X-C motif) ligand 3	4.5	2.9	2.0	3.8	5.6	2.7
TNFαIP3	TNFα-induced protein 3; inhibits NF-κB activation	4.6	3.9	4.1	4.0	2.9	2.2
NFκBIA	Inhibits NF-κB by sequestering it in cytoplasm	2.1	2.1	2.5	2.2	2.6	2.3
NFκBIZ	Molecule possessing ankyrin repeats induced by LPS	2.7	2.6	2.6	2.5	2.5	2.1
FOS	Forms transcription factor AP-1 with JUN family members	13.0 <sup>4</sup>	2.8	4.2	3.2	42.5	5.9
GEM	GTP-binding mitogen-induced protein	3.5	-	2.7	-	6.8	2.8
PTGS2	Prostaglandin-endoperoxide synthase	4.3	2.5	1.8	2.3	4.3	2.8
<b>Signal Transduction</b>							
HBEGF	Heparin-binding EGF-like growth factor	5.5	2.1	2.0	2.0	6.3	2.0
GDF15	Growth differentiation factor 15	4.2	2.3	-	2.0	6.0	2.0
MAP3K8	Mitogen-activated protein kinase kinase kinase 8	3.4	1.8	2.3	1.6	4.4	2.1
<b>Regulation of Transcription</b>							
EGR1	Early growth response 1	6.6	3.3	2.0	2.9	11.8	2.5
ZC3H12A	Zinc finger CCCH-type containing 12A	3.4	2.7	1.8	2.7	3.0	2.0
MYNN	Myoneurin	2.3	-	2.0	-	4.5	2.3
BHLHB2	Basic helix-loop-helix domain containing, class B, 2	2.3	-	2.3	-	5.6	2.7
<b>Anti-apoptosis</b>							
BIRC3	Baculoviral IAP repeat-containing 3	2.8	2.3	-	2.3	2.2	1.8
IER3	Immediate early response 3; induced by TNF	4.2	3.0	2.3	2.9	5.1	3.1

722 <sup>1</sup>Genes are classified as common if they show a fold-change  $\geq 2$  in response to all genetic strain backgrounds and at least 4 out of 6 conditions

723 <sup>2</sup>Average fold-change (FC) from three independent experiments;  $p < 0.05$

724 <sup>3</sup>-, not induced:  $FC < 1.5$

725 <sup>4</sup> $p = 0.15$

726 **Table 2. Functional categorization of pharyngeal epithelial Detroit 562 genes induced in response to adherent encapsulated**  
 727 **pneumococci.**

728

Global Classification	D39	G54	TIGR4	All 3	D39 and G54	D39 and TIGR4	G54 and TIGR4	Total
Apoptosis	0	0	5	1	0	4	2	12
Cell cycle, proliferation, and differentiation	0	3	19	1	0	3	1	27
Cytoskeleton organization and biogenesis	0	0	5	0	0	0	0	5
DNA metabolism	0	0	1	0	0	0	0	1
Extracellular matrix and adhesion	1	3	9	0	0	1	0	14
Immune response	1	0	4	7	0	5	1	18
Metabolism	1	3	6	0	0	1	2	14
Protein metabolism	0	1	1	0	0	1	0	5
Regulation of transcription	1	1	31	5	1	15	3	57
RNA metabolism	0	1	6	0	0	1	0	8
Signal transduction	2	5	18	5	0	20	5	55
Stress response	0	0	3	0	0	1	0	4
Transport and binding proteins	0	1	13	0	0	1	1	16
Unknown function	1	9	49	2	0	9	7	77
Total	7	27	170	21	1	62	22	311

729

730

730 **Table 3. Capsule-dependent response genes in pharyngeal epithelial Detroit 562 cells during pneumococcal adherence:**

731 **MAPK Signaling Pathway.**

Locus	Description / Molecular Function	Fold-change <sup>1</sup> in response to:					
		D39WT	D39Δ <i>cps</i>	G54WT	G54Δ <i>cps</i>	TIGR4WT	TIGR4Δ <i>cps</i>
ADRB2	β2-adrenergic receptor: Initiates activation of MAP kinases ERK1 and ERK2	2.3	- <sup>2</sup>	-	-	3.8	-
EGFR	Epidermal growth factor receptor	-	-	3.0	-	2.4	-
DUSP1	Dual specificity phosphatase 1: Inactivation of ERK2 by dephosphorylation	2.7	-	1.6	-	12.1	2.0
DUSP2	Inactivation of ERK1 and ERK2	2.3	-	-	-	4.9	-
DUSP4	Inactivation of ERK1, ERK2, and JNK	2.7	-	1.6	-	3.5	1.7
DUSP5	Inactivation of ERK1	3.8	-	2.2	-	7.0	1.7
DUSP6	Inactivation of ERK2	4.4	1.7	2.1	1.9	6.4	1.9
GADD45AB	Activation of MAPKKK activity (MEKK4 kinase)	2.4	-	-	-	2.7	-
MAPKAPK2	MAPK-activated protein kinase	-	-	2.2	-	-	-
MAP3K8	MAPKKK protein kinase: induces production of NF-κB	3.4	1.8	2.3	1.6	4.4	2.1
NR4A1	Nuclear receptor subfamily 4, group A, member 1	2.2	-	1.6	-	5.1	-
TRIB1	MAP2K1: activation of ERK1 and ERK2	2.2	-	1.6	-	6.7	1.8

732 <sup>1</sup>Average fold-change (FC) from three independent experiments; p<0.05

733 <sup>2</sup>-, not induced: FC<1.5

734

734 **Table 4. Functional categorization of pharyngeal epithelial Detroit 562 genes repressed in response to adherent pneumococci.**

Global Classification	D39	D39Δ <i>cps</i>	TIGR4	D39 and D39Δ <i>cps</i>	D39 and TIGR4	Total
Apoptosis	0	1	0	0	1	2
Cell cycle, proliferation, and differentiation	2	11	2	1	0	16
Cytoskeleton organization and biogenesis	0	4	0	2	0	6
DNA metabolism	0	4	1	0	0	5
Extracellular matrix and adhesion	0	5	0	3	0	8
Immune response	0	1	0	0	0	1
Metabolism	2	12	0	0	1	15
Nuclear export	0	1	0	0	1	2
Protein metabolism	0	4	2	1	0	7
Regulation of transcription	2	12	6	2	0	22
RNA metabolism	2	3	1	0	0	6
Signal transduction	1	8	0	0	0	9
Stress response	0	3	1	1	0	5
Transport and binding proteins	0	3	1	1	0	5
Unknown function	2	39	4	6	0	51
Total	11	111	18	17	3	160

735

Figure 1.




Figure 2.






Figure 3.




Figure 4.





Figure 5.




Figure 6.

